Form 4: Avalo Therapeutics Director Granted Stock Options

Avalo Therapeutics Director Rita Jain was granted 1,043 stock options with an exercise price of $18.16, fully vested on December 31, 2025.

Summary

• Director Rita Jain of Avalo Therapeutics, Inc. (AVTX) was granted 1,043 stock options.
• The options have an exercise price of $18.16 per share.
• The grant date was December 31, 2025, and the options are 100% vested on this date.
• The options expire on December 31, 2035.
• Following this transaction, Rita Jain beneficially owns 1,043 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of fully vested stock options to a director is generally viewed positively as it aligns management's interests with shareholder value creation, although it is a routine compensation disclosure.

Positives

• The grant of stock options aligns the interests of Director Rita Jain with shareholders, incentivizing long-term company performance.
• The options are fully vested on the grant date, providing immediate beneficial ownership.

Future Outlook

N/A

Industry Context

N/A

Related Party Transactions

• Grant of 1,043 stock options to Director Rita Jain by Avalo Therapeutics, Inc.

Stakeholder Impact

• Shareholders: Potential for improved alignment of director interests with shareholder value, though also potential for future dilution upon exercise.
• Director (Rita Jain): Receives equity compensation, increasing personal stake in the company's performance and future value.

Key Dates

Keywords

Avalo Therapeutics, AVTX, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Grant